Company Information

 

AVITA Medical Inc (ASX: AVH)

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo.

Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions.

The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

 

Top Australian Brokers

 

REVENUE IN AUD (TTM)

16.23m

NET INCOME IN AUD

-40.56m

Year on year AVITA Medical Inc had net income fall 112.85% from a loss of 16.52m to a larger loss of 35.16m despite a 543.96% increase in revenues from 1.27m to 8.16m.

 

AVITA Medical Inc (ASX: AVH) Live Chart

 

AVITA Medical Inc (ASX: AVH) Forecast

Based on 6 Wall Street analysts offering 12 month price targets for Avita Medical The average price target is $23.20 with a high forecast of $40.00 and a low forecast of $9.00. The average price target represents a 158.06% change from the last price of $8.99.

 

Latest ASX News

 

AVITA Medical Inc (ASX: AVH) Performance

 

AVITA Medical Inc (ASX: AVH) Fundamentals

 

AVITA Medical Inc (ASX: AVH) Competitors

 

Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2024.

We’re giving away this valuable research for FREE.

Click below to secure your copy